UroGen Pharma (URGN) Misses Q4 EPS by 4c ; Offers Guidance

UroGen Pharma (NASDAQ: URGN) reported Q4 EPS of ($0.72), $0.04 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $23.53 million versus the consensus estimate of $22.56 million.

GUIDANCE:

UroGen Pharma sees FY2024 revenue of $95-102 million, versus the consensus of $108.7 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c
• KULR Technology Group (KULR) Misses Q2 EPS by 39c